HomeCompareJAPPF vs JNJ

JAPPF vs JNJ: Dividend Comparison 2026

JAPPF yields 1.61% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JAPPF wins by $26.06M in total portfolio value
10 years
JAPPF
JAPPF
● Live price
1.61%
Share price
$15.78
Annual div
$0.25
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.09M
Annual income
$23,306,468.67
Full JAPPF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — JAPPF vs JNJ

📍 JAPPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJAPPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JAPPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JAPPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JAPPF
Annual income on $10K today (after 15% tax)
$136.89/yr
After 10yr DRIP, annual income (after tax)
$19,810,498.37/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JAPPF beats the other by $19,806,460.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JAPPF + JNJ for your $10,000?

JAPPF: 50%JNJ: 50%
100% JNJ50/50100% JAPPF
Portfolio after 10yr
$13.06M
Annual income
$11,655,609.27/yr
Blended yield
89.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JAPPF
No analyst data
Altman Z
8.3
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JAPPF buys
0
JNJ buys
0
No recent congressional trades found for JAPPF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJAPPFJNJ
Forward yield1.61%2.14%
Annual dividend / share$0.25$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$26.09M$30.5K
Annual income after 10y$23,306,468.67$4,749.88
Total dividends collected$25.85M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JAPPF vs JNJ ($10,000, DRIP)

YearJAPPF PortfolioJAPPF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,022$322.09$10,594$274.49+$428.00JAPPF
2$12,457$663.57$11,294$360.69+$1.2KJAPPF
3$14,731$1,401.82$12,133$476.91+$2.6KJAPPF
4$18,861$3,098.50$13,156$635.42+$5.7KJAPPF
5$27,596$7,415.18$14,432$854.61+$13.2KJAPPF
6$49,807$20,279.55$16,056$1,162.76+$33.8KJAPPF
7$121,709$68,414.82$18,175$1,604.53+$103.5KJAPPF
8$442,710$312,481.47$21,009$2,252.68+$421.7KJAPPF
9$2,598,254$2,124,554.34$24,911$3,229.73+$2.57MJAPPF
10$26,086,600$23,306,468.67$30,458$4,749.88+$26.06MJAPPF

JAPPF vs JNJ: Complete Analysis 2026

JAPPFStock

Japan System Techniques Co., Ltd. engages in the software business in Japan. The company offers software development services; provides business and engineering applications; and operates in medical big data business. It also offers system consultation, integration, and management and administration services; sells systems; develops and sells software package products; and provides database services. The company was incorporated in 1973 and is headquartered in Tokyo, Japan.

Full JAPPF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this JAPPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JAPPF vs SCHDJAPPF vs JEPIJAPPF vs OJAPPF vs KOJAPPF vs MAINJAPPF vs ABBVJAPPF vs MRKJAPPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.